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End-stage renal disease, atherosclerosis, and cardiovascular Several studies from the early 1970s showed that the
mortality: Is C-reactive protein the missing link? In uremic prevalence of cardiovascular diseases was significantly
patients, the morbidity and mortality of cardiovascular disease higher in uremic patients on maintenance hemodialysisare substantially higher than in the general population. This
(HD) compared with other populations of a similar agehas led to the formulation of an “accelerated atherogenesis”
[1, 3, 4]. This led to the hypothesis of an “acceleratedhypothesis in uremic patients and has been commonly linked
with the metabolic alterations associated with uremia. Ad- atherogenesis” in patients on dialysis [1]. The hypothesis
vancement in the understanding of the pathogenesis of athero- still remains a matter of controversy, but the high mortal-
sclerotic vascular disease now suggests a central contribution ity rate caused by cardiovascular complications remainsof inflammation to atherogenesis, with involvement of a num-
despite the advances achieved in dialysis technology dur-ber of key mediators and markers of the inflammatory process.
ing last two decades. The cardiovascular mortality rateRecent epidemiological data have documented associations
between C-reactive protein (CRP), the prototypical acute in dialysis patients is approximately 30 times the risk in
phase response protein, and cardiovascular disease in general the general population and remains 10 to 20 times higher
population. Given the lipoprotein binding and complement
even after stratification for age, gender, and presence ofactivation functions of CRP and its localization in atheroscle-
diabetes [5].rotic vessels, there is a strong likelihood that CRP may be
involved in the atherosclerotic process. The uremic state is Undoubtedly, end-stage renal disease (ESRD) is asso-
associated with an altered immune response, which is associ- ciated with several traditional (hypertension, hyperlipid-
ated with elevated proinflammatory cytokine levels. CRP con- emia, diabetes mellitus) and uremia-related risk factors
centrations are increased in a significant proportion of end-
(hemodynamic overload, anemia, hyperhomocysteine-stage renal disease patients and have been associated with
mia, and increased oxidative stress) for atherogenesiscertain clinical outcome measures, including all-cause and car-
diovascular mortality. This review outlines the evidence linking [6]. The major focus of interest thus far has been devoted
CRP with atherosclerosis and proposes that elevated CRP con- to finding a link between the metabolic alterations of
centrations may be involved in the initiation and progression chronic uremia and the development of atherosclerosis.of accelerated atherosclerosis in uremia.
However, over the last several years, the idea that in-
flammation plays a key role in atherosclerosis has re-
ceived considerable attention. Atherosclerosis is not a“In our retrospective study, it is not possible to provide
single disease entity, but a process consisting of the re-
evidence of the cause of the accelerated atherosclerosis.
sponses to numerous insults to the endothelium and
The possible role of renal failure as an etiologic factor
smooth muscle cells of the arterial wall. This “response-
per se cannot be neglected.” A. Lindner et al, 1974 [1]
to-injury” hypothesis is formulated by numerous obser-“Atherosclerosis is an inflammatory disease . . . the
vations in humans and animals, and the whole process
process of atherogenesis has been considered by many to
from the earliest recognizable lesion (fatty streak) to
consist largely of the accumulation of lipids within the
advanced lesions of atherosclerosis (fibrous plaques) isartery wall; however, it is much more than that.” Russell
tightly linked with an inflammatory response (Fig. 1)Ross, 1999 [2]
[reviewed in 2].
In view of the persuasive evidence implicating a key
role to inflammation in atherosclerosis, several circulat-Key words: uremia, dialysis, immune response, inflammatory disease,
fatty streak lesion, fibrous plaque, vascular disease, acute phase response. ing markers of inflammation have been examined as
potential tools for predicting the presence of vascularReceived for publication November 4, 1999
disease or the risk of vascular events [7]. Of the varietyand in revised form August 21, 2000
Accepted for publication August 24, 2000 of circulating markers, C-reactive protein (CRP), the
major acute phase response (APR) protein, has beenÓ 2001 by the International Society of Nephrology
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Fig. 1. Development of atherosclerotic lesions according to “response-to-injury” hypothesis [2]. The earliest changes that precede the formation
of atherosclerosis take place in the endothelium (endothelial dysfunction), which is the result of exposure to various toxic insults. The endothelial
cells increase expression of adhesion molecules and secrete various chemokines and growth factors. The increased adherence of monocyte/
macrophages and T-cells precede their subendothelial migration. Subendothelial macrophages become large foam cells after lipid accumulation.
The fatty streak can then progress to an intermediate lesion and ultimately to a fibrous plaque as a result of continued inflammation. The fibrous
plaques increase in size and, by projecting into the lumen, may impede the blood flow and incite further thrombogenic stimuli.
the best studied, with the most consistent relationship to matory cytokines, namely interleukin-6 (IL-6), IL-1, and
tumor necrosis factor-a (TNF-a). Its uniqueness is duefuture risk for cardiovascular events in different clinical
to rapid (within 6 hours) and dramatic increases (up tosettings in general population [reviewed in 8, 9]. Accu-
1000-fold) in circulating concentrations after a cytokine-mulating data from prospective cohort studies in ESRD
mediated response to most forms of tissue injury, infec-patients have also demonstrated an association between
tion, and inflammation [12]. Moreover, it was shown thatelevated CRP levels and all-cause and cardiovascular
plasma half-life (19 hours) and fractional clearance ratesmortality [10, 11]. In this review, we summarize the cur-
of CRP were nearly constant in normal subjects, as wellrently available evidence regarding CRP, atherosclero-
as in patients with infectious, inflammatory, and neoplas-sis, and cardiovascular disease in both the general popu-
tic conditions [13]. This marks CRP as a “precise objec-lation and uremic patients. We also consider the possible
tive index” of overall inflammatory activity and a surro-pathogenetic importance of CRP in atherosclerotic vas-
gate of underlying cytokine stimulus [14].cular disease. Elucidation of the role of CRP in the
Evidence from experimental and clinical studies hascontext of ESRD can help develop further insights for
been accumulating that CRP may contribute directly tothe hypothesis of “accelerated atherogenesis in uremia”
the pathogenesis of atherosclerosis and its complicationsand potential starting points for preventive measures.
through a variety of mechanisms.
(1) CRP binds to damaged cells and activates the com-
CRP, ATHEROSCLEROSIS, AND plement system. This binding action means that CRP has
CARDIOVASCULAR DISEASE a potential pathogenetic role in foam cell formation and
C-reactive protein is the prototypical APR protein pro- in promoting atherosclerotic lesions [15]. Torzewski et
al recently demonstrated that majority of foam cells be-duced by the liver under the control of various proinflam-
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low the endothelium show positive staining for CRP, structure–function relationships of CRP have just be-
and there is a diffuse deposition of CRP in deep fibro- come clarified [32]. However, there is indirect evidence
elastic and fibromuscular layers of the intima with acti- that the classic treatments used in preventing cardiovas-
vated complement components [16]. CRP is also found cular diseases may act through mechanisms interfering
deposited in the infarcted myocardium, together with with inflammatory mechanisms and CRP [9, 27, 33, 34].
activated complement components [17] and parenteral In the U.S. Physicians’ Health Study, the use of aspirin
injection of CRP markedly enhances tissue damage, via was associated with a significant reduction in the risk of
a complement-dependent mechanism, in experimental myocardial infarction among men in the highest quartile
myocardial infarction [15]. of CRP (55.7%) compared with those in the lowest
(2) CRP displays calcium-dependent in vitro binding quartile (13.9%) [49]. In a secondary prevention trial, it
and aggregation of low-density lipoprotein (LDL) and very was shown that pravastatin treatment significantly atten-
LDL (VLDL) [18]. Bhakdi et al recently demonstrated uates the effect of inflammation on cardiovascular risk
that CRP binds to enzymatically degraded LDL particles [33]. Long-term follow-up of these patients (5 years)
and colocalizes with these lipid particles in early human revealed that pravastatin resulted in a significant reduc-
atherosclerotic lesions [19]. tion in CRP levels (21.6% reduction in median CRP, P 5
(3) CRP is a potent stimulator of tissue factor production
0.007) compared with those on placebo [34].
by monocytes [20], and the effect is augmented in the
presence of other inflammatory mediators [21]. This in-
teraction between CRP, inflammatory mediators, and CRP, ESRD, AND ATHEROSCLEROSIS
tissue factor provides new insights into mechanisms link-
C-reactive protein, in accord with its classic role, is useding inflammation and coagulation, which may contribute
as a marker of infection or activity parameter of ongoingto the progression and outcome of atherosclerotic vascu-
inflammatory disease in ESRD patients. Several obser-lar diseases.
vations during the last decade, however, have demon-Several epidemiological studies and clinical observations
strated that CRP is elevated in a significant proportionhave strengthened these possible pathogenetic associa-
of ESRD patients without any apparent reason (Table 1).tions between CRP and atherosclerosis and its complica-
The first observation by Sethi et al showed that CRPtions. CRP was associated with the degree of athero-
was elevated in one third of the HD patients. In this study,sclerosis in coronary, peripheral, and extracranial brain
CRP was correlated with the length of time on dialysisarteries [22]. High CRP levels were significantly linked
to future event risk in stable [23] and unstable [24, 25] but remained unchanged during a single dialysis session
angina patients. Breakthrough clinical evidence for CRP [35]. Later studies reported controversial results for the
is established following prospective epidemiological correlations between CRP, length of time on dialysis,
studies among apparently healthy adults [26–29]. In the and dialysis session [36, 45, 46]. Haubitz, Schulze, and
U.S. Physicians’ Health Study, Ridker et al showed that Koch, by using a sensitive CRP assay, showed a signifi-
men with CRP levels in the highest quartile had a three- cant increase 24 hours after a dialysis session. As CRP
fold increase in the risk of developing a myocardial in- levels usually increase 8 to 12 hours after the initial insult,
farction (relative risk 2.9, P , 0.001) and twice the risk of the methodology of this study is more relevant than
developing a stroke (relative risk 1.9, P 5 0.02) compared immediate measurements [47].
with men with levels in the lowest quartile. These risk C-reactive protein elevation is not only limited to the
estimates were found to be stable over an 8- to 10-year HD population. Elevated CRP levels were reported in
follow-up and were independent of other cardiovascular ESRD patients on either conservative treatment or peri-
risk factors [27]. In many of these studies, CRP was
toneal dialysis (PD; Table 1). Haubitz et al showed that
associated with other known cardiovascular risk factors,
highest values were in HD patients compared with PDsuch as increasing age, smoking, fibrinogen levels, and
or conservative treatment groups [48], whereas Kaysenplasma lipids [26]. CRP, however, remains an indepen-
observed that CRP levels were significantly greater in PDdent and strong predictor for cardiovascular disease even
patients than in HD patients (unpublished observations)after adjusting for these confounding factors. CRP also
[49]. In contrast to an earlier study [36], several studiesappears to be a more powerful risk factor for coronary
have demonstrated significantly elevated CRP levels inartery disease than lipid-type risk factors [30, 31].
ESRD patients on conservative treatment [42, 46, 48, 50].An invaluable way of confirming an association be-
Interestingly, in one of these studies, serum samples ob-tween elevated CRP and atherogenesis is disclosing a
tained from eight individual patients 6, 12, and 18 weekstherapeutic challenge that controls APR, and hence CRP
after the initiation of chronic HD treatment showed aproduction, or one that prevents the proinflammatory
significant increase in CRP levels compared with levelsactions of CRP. This is very difficult to achieve as there is
no single factor controlling CRP secretion and molecular before starting HD [48].
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Table 1. A chronological summary of clinical studies that assessed elevated C-reactive protein (CRP) prevalence in end-stage renal disease
(ESRD) patients
Sensitivity Patients with
Author Year Study group Methoda (normal range)b high CRP %
Sethi et al [35] 1988 99 (HD) End-point immunonephelometry 5 mg/L (,10 mg/L) 35 (HD)
Docci et al [36] 1990 30 (C) Nephelometric immunoassay 2.7 mg/L (,5 mg/L) 40.6 (HD)
30 (CRF)
69 (HD)
McIntyre et al [37] 1997 98 (HD) Immunoturbidometry ND (,10 mg/L) 53 (HD)
68 (PD) 25 (PD)
Quereshi et al [38] 1998 44 (C) Immunonephelometry ND (10 mg/L) 53 (HD)
128 (HD)
Owen et al [39] 1998 988 (HD) Rate nephelometry ND (,8 mg/L) 35 (HD)
Noh et al [40] 1998 105 (PD) End point nephelometry ND (#8 mg/L) 12 (PD)
Creed [41] 1998 112 (HD) ND ND (0–5 mg/L) 65 (HD)
Zimmermann et al [10] 1999 160 (C) Nephelometric immunoassay ND (,8 mg/L) 46 (HD)
280 (HD)
Stenvinkel et al [42] 1999 109 (CRF) ND 10 mg/L (ND) 32 (CRF)
22 (C)
Iseki et al [43] 1999 163 (HD) Turbimetric immunoassay ND (,6 mg/L) 21 (HD)
Panichi et al [44] 2000 201 (HD) Laser nephelometry 1 mg/L (0.1–4.0 mg/L) 47 (HD)
Abbreviations are: ND, no data; C, normal healthy control; CRF, predialysis chronic renal failure patients; HD, chronic hemodialysis patients; PD, peritoneal
dialysis patients.
a As mentioned in the study
b All CRP values are expressed in terms of mg/liter
Potential sources of elevated CRP in ESRD volumes. They proposed that backfiltration of bacteria-
derived contaminants during dialysis (with high-perme-The uremic state is associated with an altered immune
ability membranes or low-volume hemodiafiltration)response. A wide variety of factors in ESRD and espe-
may induce a chronic inflammatory state [44]. The limita-cially in HD are capable of stimulating monocyte/macro-
tions of both studies warrant further studies to determinephages to induce cytokine release [51]. Several studies
whether one or both of these factors are operative inhave shown that proinflammatory cytokines were in-
activating APR in HD.creased in predialysis uremic patients, as well as dialysis
Exposure of blood to dialysate or dialysis membranespatients [52–54]. This suggests that uremia per se may
may not be the sole source of inflammation, as half ofcause a proinflammatory status with ongoing APR [42].
the HD patients have a normal serum CRP level [49].In the heretofore established proinflammatory background
The highly skewed distribution of CRP as well as IL-6of uremia, extracorporeal circulation of blood during
suggests that patient-specific processes, such as the typeeach HD session may act as a fresh stimulus for APR.
of vascular access [58] or unrecognized infections [38],Exposure of circulating mononuclear cells to the dialysis
may also play a role in inciting an inflammatory response.membrane [55] or exposure of circulating blood to lipo-
The source of elevated CRP in PD patients is notpolysaccharide on the dialysate site of the membrane is
obvious, either. Libetta et al reported that PD patientsa potential source for increased cytokine levels [56].
had comparable levels of mononuclear cell activation,The two earlier studies that assessed the role of dialysis
suggesting a bioincompatibility of peritoneal dialysatemembranes on CRP production yielded equivocal results
solutions [59]. Exposure of the peritoneal membrane to[36, 45]. A recent crossover study measuring CRP levels
plasticizers found in dialysate or transperitoneal access24 hours after a dialysis session demonstrated that CRP
is suggested as a probable source of inflammation in PDwas significantly increased following HD with bioincom-
patients [49, 60].patible (cuprammonium) compared with a relatively bio-
compatible membrane (polysulfon) [57]. They also re-
Clinical significance of elevated CRP in ESRDported that patients who had undergone an ultrapure
The presence of an elevated CRP in a significant num-dialysis with cuprammonium membrane had similar pat-
ber of ESRD patients, particularly the HD population,terns of increase in IL-6 and CRP. They suggested that
confirms the existence of chronically activated APR. Al-the type of membrane, rather than the bacterial quality
though it is usually a beneficial response, the untowardof the dialysate, was responsible for the induction of the
effects of excessive and enduring APR already have beenAPR during HD [57]. However, Panichi et al, in a large
defined in the general population [14]. Recent data fromgroup of HD patients (N 5 201), have demonstrated
ESRD patients also showed that elevated CRP levelsthat values of CRP and IL-6 were significantly higher in
patients undergoing hemodiafiltration with low exchange have significant associations with hypoalbuminemia,
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Table 2. Summary of clinical studies that assessed elevated CRP as a predictor of clinical outcome in ESRD patients
Follow-up duration
Author Year Study group months Outcome parameter Outcome predictor
Bergstro¨m et al (abstract) 1995 128 (HD) 48 All-cause mortality CRP
Owen et al [39] 1998 1054 (HD) 6 All-cause mortality Alb, Cre, TLC, not CRP
Noh et al [40] 1998 106 (PD) 24 All-cause mortality CRP, CVD, Hct
Ikizler et al [63] 1999 73 (HD) 15 Hospitalization CRP, LBM
Zimmermann et al [10] 1999 280 (HD) 24 All-cause and cardiovascular mortality CRP, age
Iseki et al [43] 1999 163 (HD) 84 All-cause mortality CRP
Yeun et al [11] 2000 91(HD) 34 All-cause and cardiovascular mortality CRP, age
Abbreviations are: Alb, albumin; Cre, creatinine; TLC, total lymphocyte count; CVD, cardiovascular disease; LBM, lean body mass; Hct, hematocrit.
malnutrition, erythropoietin resistance, and most nota- PD patients was significantly lower in the elevated CRP
group than in the normal CRP group (66.7 vs. 94.1%) [40].bly increased morbidity and mortality in both HD and
PD patients (Table 2) [61, 62].
CRP and cardiovascular disease in ESRDIn their preliminary observation, Bergstro¨m et al were
In keeping with the literature from the general popula-first to show that elevated CRP was a strong predictor
tion, there are emerging data in patients with ESRDof mortality over one and three years in HD patients.
linking CRP and cardiovascular disease. CRP levels wereCRP appeared to be an independent predictor of survival
found to be associated with various classic markers ofeven after adjusting for other variables (abstract; Berg-
cardiovascular disease, such as lipoprotein (a) [10, 46,stro¨m et al, J Am Soc Nephrol 6:573, 1995). In an uncon-
50], fibrinogen, and low high-density lipoprotein [10] introlled, observational analysis of 988 HD patients, Owen
ESRD populations. Two cross-sectional studies demon-and Lowrie showed the association between CRP and
strated that elevated CRP levels were associated withnutritional measures, but were unable to find any rela-
surrogate markers for atherosclerotic vascular disease intionship between CRP and the odds risk of death [39].
both HD [41] and predialysis [42] patients. Cardiovascu-Ikizler et al, using hospitalization as an outcome marker
lar Risk Extended Evaluation in Dialysis (CREED) in-of morbidity, showed that 15% of the patients were hos-
vestigators showed that CRP was an independent pre-
pitalized in the lowest CRP quartile (values less than 0.2 dictor of the number of atherosclerotic plaques in carotid
mg/dL), whereas this number was increased to 48% in arteries of 112 chronic HD patients [41]. Stenvinkel et
the highest quartile of CRP (higher than 1.4 mg/dL) [63]. al detected a significantly increased intima-media thick-
Three recent studies showed that CRP was a signifi- ness in carotid arteries of predialysis patients with CRP
cant and independent predictor of death in chronic HD levels $10 mg/L (20.1 6 1.0 mm2) compared with those
patients. In a prospective cohort analysis of 288 HD with CRP ,10 mg/L (17.5 6 0.6 mm2, P , 0.05). An
patients, Zimmermann et al showed that all-cause and additional observation in this study was significantly pos-
cardiovascular mortality was higher in patients with ele- itive correlation between CRP and oxidized LDL levels
vated CRP, being 31 and 16%, respectively. Moreover, [42]. This suggests a possible relationship between in-
patients in the highest quartile of CRP had a 4.6-fold creased oxidative stress in ESRD and inflammation,
and 5.5-fold higher risk of all-cause and cardiovascular which warrants further studies to elucidate a “causal”
interference.mortality in comparison to patients in lowest quartile
Two prospective studies have extended this link be-[10]. Iseki et al showed a poorer survival in patients with
tween CRP and surrogate markers of atherosclerosis toelevated CRP (5-year survival rate of 44.4%) compared
cardiovascular mortality in HD patients [10, 11]. Zim-with normal CRP (5-year survival rate of 82.5%) in a
merman et al found that cardiovascular mortality wasseven-year follow-up in 163 HD patients [43]. Yeun et
significantly increased with each increasing quartile ofal also identified CRP levels as the most powerful pre-
CRP, the highest quartile having a relative risk of 5.48dictor of all-cause and cardiovascular mortality in 91 HD
[10]. Yeun et al observed a similar association betweenpatients followed for 34 months. Patients with CRP levels
CRP and cardiovascular mortality. In the Cox propor-in the highest quartile (.11.5 mg/L) had the lowest sur-
tional hazard model, only CRP and age remained asvival, with the survival curve becoming flatter as CRP
predictors of cardiovascular mortality rather than otherlevels decreased to 5.3 to 11.5 mg/L and lower values
traditional risk factors [11].
(Table 2) [11].
Although PD patients usually have lower CRP levels in
CONCLUSIONcomparison to HD, increased CRP also appears as an
independent predictor of mortality in these patients. Noh There is a clear link between CRP and cardiovascular
disease in general population. Emerging data from ESRDet al observed that two-year patient survival among 106
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Fig. 2. Interrelationship between classic and uremia-related risk factors for atherosclerosis and the C-reactive protein (CRP). CRP is proposed
to have a midway location in the complex events leading to accelerated atherosclerosis in uremia.
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